Antisense technology to lower LDL cholesterol

In a small study in patients with heterozygous familial hypercholesterolaemia, given the same mipomersen regimen for only 13 weeks, liver fat was measured by proton magnetic resonance spectroscopy in all participants.6 The investigators of that study noted a small increase in hepatic lipid content,...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2010-03, Vol.375 (9719), p.959-961
Main Authors: Neely, R Dermot G, Bassendine, Margaret F
Format: Article
Language:English
Subjects:
Anticholesteremic Agents - therapeutic use
Apolipoprotein B-100 - antagonists & inhibitors
Apolipoprotein B-100 - biosynthesis
Cardiovascular disease
Cholesterol
Cholesterol, LDL - blood
Humans
Hyperlipoproteinemia Type II - blood
Hyperlipoproteinemia Type II - drug therapy
Internal Medicine
Metabolic syndrome
Oligonucleotides - therapeutic use
Oligonucleotides, Antisense - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a small study in patients with heterozygous familial hypercholesterolaemia, given the same mipomersen regimen for only 13 weeks, liver fat was measured by proton magnetic resonance spectroscopy in all participants.6 The investigators of that study noted a small increase in hepatic lipid content, from a low baseline of 1.2% to 2.1%; however, greater accumulation could occur after long-term treatment. Because high-intensity statin treatment, as coadministered to most patients in both studies, could restrict triglyceride accumulation by increasing the hepatic oxidation of fatty acids,7 steatosis might develop most rapidly with monotherapy.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(10)60364-9